<DOC>
	<DOCNO>NCT02566811</DOCNO>
	<brief_summary>The primary aim trial determine whether lymphadenectomy , use restrict adjuvant therapy ( vaginal brachytherapy ) node positive woman , result non-inferior survival compare adjuvant therapy give woman high risk apparent stage 1 endometrial cancer .</brief_summary>
	<brief_title>Selective Targeting Adjuvant Therapy Endometrial Cancer ( STATEC )</brief_title>
	<detailed_description>Results trial potential change practice whatever result : either lymphadenectomy become recommended practice non-inferior outcome obtain ; otherwise procedure safely abandon . Secondary Objectives - Disease-free , endometrial cancer-event free endometrial cancer-specific survival - Distribution pelvic extra-pelvic relapse - Cost effectiveness - Surgical adverse event There also two sub-studies : 1 . Quality life - patient . Describe trajectory key patient report outcomes ( PROs ) baseline 5 year post-surgery ii . Compare specific PRO domains trial arm several specific time point iii . Determine proportion woman trial arm reporting long-term symptom treatment measure symptom-specific subscales measure ( gastrointestinal symptom , urological symptom , attitude disease treatment , vaginal symptom , lymphoedema ) iv . Determine correlation physician rating ( CTCAE v4.03 ) patient-report ( corresponding PRO subscale ) various symptom report physicians patient v. Assess correlation self-assessed lymphoedema ( Self-report lower-extremity lymphoedema screen questionnaire ) lymphoedema subscale Quality Life Questionnaire-Endometrial Cancer Module ( QLQ-EN24 ) We hypothesise quality life well patient lymphadenectomy arm considerable proportion spar systemic adjuvant treatment , may benefit . 2 . Sentinel lymph node ( SLN ) - optional Arm 1 patient The aim sub-study ass SLN status comparison overall lymph node status full lymph node dissection ( LND ) , determine whether SLN accurate systematic node dissection . . We aim determine diagnostic performance SLN procedure compare gold standard LND ii . To evaluate whether SLN status prognostic marker survival iii . To model patient relapse survival base low volume micro-metastatic ( LVM ) individual tumour cell ( ITC ) status</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Histologically confirm high risk apparent International Federation Gynecology Obstetrics ( FIGO ) stage I endometrial cancer accord one follow subtypes : 1 . FIGO grade 3 endometrioid mucinous carcinoma 2 . High grade serous , clear cell , undifferentiated dedifferentiate carcinoma mixed cell adenocarcinoma carcinosarcoma Surgery perform ≤ 5 week randomisation patient randomise prior hysterectomy BSO . Patients randomise Arm 1 hysterectomy BSO must undergo lymphadenectomy ≤ 5 week randomisation Written inform consent No prior anticancer therapy endometrial cancer Eastern Cooperative Oncology Group ( EGOC ) performance status 02 Life expectancy &gt; 3 month Age ≥ 16 year Adequate organ bone marrow function Ability undergo postoperative chemotherapy without radiotherapy Adjuvant treatment commence ≤ 8 week surgery Willingness ability complete Quality Life questionnaires Grossly enlarge node ( ) ≥ 10 mm short axis baseline radiological image Invasion cervical stroma baseline radiological image obvious cervical disease clinical examination Involvement uterine serosa metastatic disease see outside uterus baseline radiological image Small cell carcinoma neuroendocrine differentiation Concurrent anticancer therapy Previous malignancy &lt; 5 year prior randomisation concurrent malignant disease exception : 1. carcinoma situ cervix 2. nonmelanoma skin cancer 3. basal cell carcinoma 4. melanoma situ Women pregnant lactating</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>